Can You Treat Psoriasis With Essential Oils?
Psoriasis is a common skin condition. What is it and what causes it? Learn how essentials oils and natural remedies may be used to treat psoriasis.
Monthly Archives: October 2016
Indoor tanning associated with poor outdoor sun protection practices
Adults who frequently tanned indoors - a practice associated with an increased risk for melanoma - also practiced poor outdoor sun protection practices and were not more likely to undergo skin...
Breast cancer drug shows potential in patients with skin metastases
A study presented at the ESMO Congress reveals how the drug tucatinib led to a reduction in skin metastases for patients with breast cancer.
Diabetes: New hope for better wound healing
A sluggish insulin metabolism results in the slow and incomplete healing of injuries. That is why diabetics often have to contend with wounds that heal poorly.
CU researchers identify genes related to vitiligo
For the past decade, Richard Spritz's lab at the University of Colorado Anschutz Medical Campus has been searching for potential causes of vitiligo, an autoimmune disease that gives rise to patches...
Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma
Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first...
Plaque psoriasis: CIMZIA (certolizumab pegol) Phase 3 trial results
UCB and Dermira, Inc. have announced topline results from CIMPASI-2, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the efficacy and safety of CIMZIA® (certolizumab...
Phase 3 results for Sun Pharma’s investigational psoriasis medicine, tildrakizumab
Sun Pharma has announced late-breaking data from two pivotal Phase-3 clinical trials (reSURFACE 1 and 2) achieving the primary endpoint with tildrakizumab, an investigational IL-23p19 inhibitor, in...
Psoriasis: Phase 3 guselkumab VOYAGE 1 data presented at EADV Congress
Janssen Research & Development, LLC (Janssen) has announced findings from the first of three pivotal Phase 3 studies evaluating guselkumab, a subcutaneously administered anti-interleukin (IL)-23...